- Origin Therapeutics Holdings (ORIG) has added Clairvoyant Therapeutics to its portfolio
- Clairvoyant is a Canadian biotech company developing psychedelic drug therapy with a focus on treatments for addiction
- Clairvoyant is undertaking a Health Canada-approved Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use disorder (AUD)
- Origin Therapeutics Holdings Inc is an investment issuer focused on making equity investments in psychedelics industry-related companies
- Origin Therapeutics Holdings Inc. was unchanged at $0.07 at 10:09 ET
Origin Therapeutics Holdings (ORIG) has announced the addition of Clairvoyant Therapeutics to its portfolio.
Clairvoyant is a Canadian biotech company developing psychedelic drug therapy with a focus on treatments for addiction and the clinical validation of psilocybin in the E.U., the U.K., and Canada.
Clairvoyant is undertaking a Health Canada-approved Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use disorder (AUD).
This randomized, controlled, clinical trial will evaluate the safety and efficacy of a 25mg synthetic psilocybin capsule versus placebo, delivered in conjunction with Motivational Enhancement Therapy.
“Psychedelic medicine delivered in conjunction with therapy has been demonstrated by compelling clinical research to have potentially profound positive effects on those suffering from substance use disorders,” noted Alexander Somjen, CEO of Origin Therapeutics.
“Clairvoyant has a unique speed-to-market strategy for psilocybin therapy and an experienced drug development team. We believe that Clairvoyant makes an excellent addition to our portfolio,” he added.
Alcohol use disorder is a serious medical condition for which novel therapies are urgently needed.
“We are in the midst of a substance abuse crisis, and psychedelic therapies have the potential to provide patients with a new therapeutic intervention rather than having those patients be limited to options that often do not work or that may have unpleasant side effects,” stated Damian Kettlewell, CEO of Clairvoyant.
“We are pleased to be working with the Origin Therapeutics team to drive our vision forward,” he added.
Origin Therapeutics Holdings Inc is an investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector.
Origin Therapeutics Holdings Inc. was unchanged at $0.07 at 10:09 ET.
